Chapter 1. DIABETES DIGITAL THERAPEUTICS MARKET – Scope & Methodology

1.1. Market Segmentation

1.2. Assumptions

1.3. Research Methodology

1.4. Primary Sources

1.5. Secondary Sources

Chapter 2. DIABETES DIGITAL THERAPEUTICS MARKET – Executive Summary

2.1. Market Size & Forecast – (2024 – 2030) ($M/$Bn)

2.2. Key Trends & Insights

2.3. COVID-19 Impact Analysis

      2.3.1. Impact during 2024 - 2030

      2.3.2. Impact on Supply – Demand

Chapter 3. DIABETES DIGITAL THERAPEUTICS MARKET – Competition Scenario

3.1. Market Share Analysis

3.2. Product Benchmarking

3.3. Competitive Strategy & Development Scenario

3.4. Competitive Pricing Analysis

3.5. Supplier - Distributor Analysis

Chapter 4. DIABETES DIGITAL THERAPEUTICS MARKET  - Entry Scenario

4.1. Case Studies – Start-up/Thriving Companies

4.2. Regulatory Scenario - By Region

4.3 Customer Analysis

4.4. Porter's Five Force Model

       4.4.1. Bargaining Power of Suppliers

       4.4.2. Bargaining Powers of Customers

       4.4.3. Threat of New Entrants

       4.4.4. Rivalry among Existing Players

       4.4.5. Threat of Substitutes

Chapter 5.DIABETES DIGITAL THERAPEUTICS MARKET - Landscape

5.1. Value Chain Analysis – Key Stakeholders Impact Analysis

5.2. Market Drivers

5.3. Market Restraints/Challenges

5.4. Market Opportunities

Chapter 6. DIABETES DIGITAL THERAPEUTICS MARKET – By Device Type

6.1. Handheld Devices

6.2. Wearable Devices

Chapter 7. DIABETES DIGITAL THERAPEUTICS MARKET – By Product and Services

7.1. Devices

7.2. Applications

7.3. Data Management Software and platforms

7.4. Services

Chapter 8. DIABETES DIGITAL THERAPEUTICS MARKET – By End-User:

8.1. Self/Home Healthcare

8.2. Hospitals And Speciality Diabetes Clinics

8.3. Academic And research institutes

Chapter 9. DIABETES DIGITAL THERAPEUTICS MARKET – By Region

9.1. North America

9.2. Europe

9.3. The Asia Pacific

9.4. Latin America

9.5. The Middle East

9.6. Africa

Chapter 10. DIABETES DIGITAL THERAPEUTICS MARKET – Company Profiles – (Overview, Product Portfolio, Financials, Developments)

10.1. Medtronic (Ireland)

10.2.  B. Braun Melsungen AG (Germany)

10.3. Dexcom, Inc. (US)

10.4. Abbott Laboratories (US)

10.5. F. Hoffmann-La Roche (Switzerland),

10.6. Insulet Corporation (US)

10.7. Tandem Diabetes Care (US),

10.8. Ascensia Diabetes Care Holdings AG (Switzerland)

10.9. LifeScan, Inc. (US)

10.10. Tidepool (US)

10.11. AgaMatrix (US)

10.12. Glooko, Inc. (the US)

10.13. DarioHealth Corporation (Israel)

10.14. One Drop (US)

10.15. Dottli (Finland)

10.16. ARKRAY (Japan)

10.17. Ypsomed Holding AG (Switzerland)

10.18. ACON Laboratories

10.19. Inc. (US)

10.20. Care Innovations, LLC (US)

10.21. Health2Sync (Taiwan)

10.22. Emperra GmbH E-Health Technologies (Germany)

10.23. Azumio (US)

10.24. Decide Clinical Software GmbH (Austria)

10.25. Pendiq GmbH (Germany)

10.26. BeatO (India)